The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Investigation of lifestyle risks exposure as response predictor of gefitinib in non-small cell lung cancer patients.
Y. Wang
No relevant relationships to disclose
H. Ying
No relevant relationships to disclose
X. S. Wang
No relevant relationships to disclose
Q. Shi
No relevant relationships to disclose
S. Chen
No relevant relationships to disclose